Phaseline

Targets › CRAF

CRAF: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2028.

Open in Phaseline: the race on CRAF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Institut de Recherches Internationales ServierS241656
RAF inhibitor targeting all classes of oncogenic BRAF alterations (Classes I, II, and III)
BRAF, CRAF, KRAS, NRASPhase 1Non-small Cell Lung CancerJun 2028

Conditions

Non-small Cell Lung Cancer (1)

Modalities

mixed (1)

Companies

Institut de Recherches Internationales Servier (1)

Related targets

BRAF (1) KRAS (1) NRAS (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.